Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.45 |
| ▸ | BCHE | P06276 | 7/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996848 | 0.78 | NPC1 (0.54) | HTR6BCHE | |
| SCHEMBL3611707 | 0.77 | HTR6 (0.67) | HTR6BCHEHDAC3HDAC4HDAC1 | |
| SCHEMBL1993536 | 0.71 | HTR6 (0.65) | HTR6HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4021090 | 0.69 | HTR6 (0.55) | HTR6BCHE | |
| SCHEMBL4027624 | 0.69 | HTR6 (0.47) | HTR6 | |
| SCHEMBL4018797 | 0.68 | HTR6 (0.71) | HTR6 | |
| SCHEMBL3622891 | 0.67 | HTR6 (0.56) | HTR6BCHE | |
| Hydrochloric Acid SCHEMBL27567030 | 0.67 | HTR6 (0.58) | HTR6BCHE | |
| SCHEMBL4021085 | 0.66 | HTR6 (0.54) | HTR6BCHE | |
| SCHEMBL3607517 | 0.66 | HTR6 (0.63) | HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960374-B2 | e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics | PROXIMAGEN LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | HTR6 1/4885BCHE 1295/4885HDAC3 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.